Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
Cambron M, Mostert J, D'Hooghe M, Nagels G, Willekens B, Debruyne J, Algoed L, Verhagen W, Hupperts R, Heersema D, De Keyser J; FLUOX-PMS Study Group. Cambron M, et al. Among authors: willekens b. Mult Scler. 2019 Nov;25(13):1728-1735. doi: 10.1177/1352458519843051. Epub 2019 Jun 20. Mult Scler. 2019. PMID: 31218911
Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis.
De Ridder D, Van Der Aa F, Debruyne J, D'hooghe MB, Dubois B, Guillaume D, Heerings M, Ilsbroukx S, Medaer R, Nagels G, Seeldrayers P, Van Landegem W, Willekens B, Zicot AF. De Ridder D, et al. Among authors: willekens b. Clin Neurol Neurosurg. 2013 Oct;115(10):2033-40. doi: 10.1016/j.clineuro.2013.06.018. Epub 2013 Jul 20. Clin Neurol Neurosurg. 2013. PMID: 23880016
Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors.
Thewissen K, Nuyts AH, Deckx N, Van Wijmeersch B, Nagels G, D'hooghe M, Willekens B, Cras P, Eijnde BO, Goossens H, Van Tendeloo VF, Stinissen P, Berneman ZN, Hellings N, Cools N. Thewissen K, et al. Among authors: willekens b. Mult Scler. 2014 Apr;20(5):548-57. doi: 10.1177/1352458513505352. Epub 2013 Sep 20. Mult Scler. 2014. PMID: 24057429
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Cambron M, Mostert J, Haentjens P, D'Hooghe M, Nagels G, Willekens B, Heersema D, Debruyne J, Van Hecke W, Algoed L, De Klippel N, Fosselle E, Laureys G, Merckx H, Van Wijmeersch B, Vanopdenbosch L, Verhagen W, Hupperts R, Hengstman G, Michiels V, Van Merhaegen-Wieleman A, De Keyser J. Cambron M, et al. Among authors: willekens b. Trials. 2014 Jan 25;15:37. doi: 10.1186/1745-6215-15-37. Trials. 2014. PMID: 24460863 Free PMC article. Clinical Trial.
Except for C-C chemokine receptor 7 expression, monocyte-derived dendritic cells from patients with multiple sclerosis are functionally comparable to those of healthy controls.
Nuyts AH, Ponsaerts P, Van Tendeloo VF, Lee WP, Stein B, Nagels G, D'hooghe MB, Willekens B, Cras P, Wouters K, Goossens H, Berneman ZN, Cools N. Nuyts AH, et al. Among authors: willekens b. Cytotherapy. 2014 Jul;16(7):1024-30. doi: 10.1016/j.jcyt.2014.02.016. Epub 2014 May 20. Cytotherapy. 2014. PMID: 24856897 Free article.
Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
van Pesch V, Bartholomé E, Bissay V, Bouquiaux O, Bureau M, Caekebeke J, Debruyne J, Declercq I, Decoo D, Denayer P, De Smet E, D'hooghe M, Dubois B, Dupuis M, Sankari SE, Geens K, Guillaume D, van Landegem W, Lysandropoulos A, de Noordhout AM, Medaer R, Melin A, Peeters K, Ba RP, Retif C, Seeldrayers P, Symons A, Urbain E, Vanderdonckt P, Van Ingelghem E, Vanopdenbosch L, Vanroose E, Van Wijmeersch B, Willekens B, Willems C, Sindic C. van Pesch V, et al. Among authors: willekens b. Acta Neurol Belg. 2014 Sep;114(3):167-78. doi: 10.1007/s13760-014-0308-9. Epub 2014 Jun 11. Acta Neurol Belg. 2014. PMID: 24915752
The effectiveness of a self-management occupational therapy intervention on activity performance in individuals with multiple sclerosis-related fatigue: a randomized-controlled trial.
Kos D, Duportail M, Meirte J, Meeus M, D'hooghe MB, Nagels G, Willekens B, Meurrens T, Ilsbroukx S, Nijs J. Kos D, et al. Among authors: willekens b. Int J Rehabil Res. 2016 Sep;39(3):255-62. doi: 10.1097/MRR.0000000000000178. Int J Rehabil Res. 2016. PMID: 27182847 Clinical Trial.
119 results